AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN PATIENTS WITH ADVANCED SOLID TUMORS EXPRESSING CLAUDIN 18.2
||Hengrui USA, Ltd.
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
This is a Phase I/IIa study, which means that there is some but limited clinical experience in SHR-A1904 (the study drug) clinical trials conducted outside the USA. In this study, the sponsor (Jiangsu Hengrui Pharmaceuticals Co., Ltd.) and study doctors want to learn: How much of the study drug can be given with an acceptable level of side effects. About the safety and tolerability of the study drug. If the bodys immune system has a response to the study drug. The effects of the study drug (good and bad). How much of the study drug is absorbed into the blood and how fast it is removed. If research tests can be used in the future to predict who will benefit from the study drug. Cancers include: colon and rectal cancer, esophageal cancer, lung cancer, pancreatic cancer, and stomach cancer.
Ryan Moy, MD
|Are you at least 18 years old?
|Have you been diagnosed with an advanced solid tumor?